US healthcare giant Johnson & Johnson today announced that the European Commission (EC) has approved the expansion for the marketing authorization for Tremfya (guselkumab) to include a subcutaneous ...

Guselkumab offers the flexibility of self-administration from the start of treatment in both ulcerative colitis (UC) and Crohn’s disease (CD),1,2,3 providing the simplicity of a fully subcutaneous ...

Q3 2025 Earnings Call Transcript October 14, 2025 Johnson & Johnson beats earnings expectations. Reported EPS is $2.8, ...

J&J (NYSE:JNJ) announced on Tuesday that its FDA-approved antibody therapy, Tremfya, as a subcutaneous option, improved a range of clinical and endoscopic measures in patients with the intestinal ...

NEW YORK - Johnson & Johnson (NYSE:JNJ) announced on Tuesday that its ulcerative colitis treatment TREMFYA (guselkumab) demonstrated clinically meaningful results in both clinical and endoscopic ...

The U.S. Food and Drug Administration has approved Johnson & Johnson's Tremfya (guselkumab) for the treatment of plaque psoriasis and active psoriatic arthritis in children 6 years of age and older.

Johnson & Johnson (NYSE:JNJ) ranks among the top picks for a retirement portfolio. On September 26, Johnson & Johnson (NYSE:JNJ) reported that the US FDA had approved a subcutaneous induction protocol ...

THURSDAY, Oct. 2, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Tremfya (guselkumab) for the treatment of plaque psoriasis and active psoriatic arthritis in children 6 ...